by Sermonix Pharmaceuticals | Sep 23, 2019 | News
Sept. 26 presentation in Chicago demonstrates the need for improvement in practitioners’ understanding of patients’ intimacy concerns COLUMBUS, Ohio, Sept. 25, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on...
by Sermonix Pharmaceuticals | Jun 3, 2019 | News
Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and D538G tumors to the lungs and liver.Lasofoxifene, in combination with...
by Sermonix Pharmaceuticals | Jun 2, 2019 | News
CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like palbociclib, is a promising approach for the treatment of endocrine therapy resistant ER+ metastatic breast cancer patients (Abstract 1056). “Lasofoxifene is a legacy molecule...
by Sermonix Pharmaceuticals | May 28, 2019 | News
Designation allows for expedited development and review of lasofoxifene as a potential precision medicine treatment for women who have estrogen receptor-positive (ER+) metastatic breast cancer with an ESR1 mutation COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) —...
by Sermonix Pharmaceuticals | May 7, 2019 | News
Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib versus fulvestrant and palbociclib in animal models. COLUMBUS, Ohio (May 7, 2019) – Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the...
Recent Comments